Press release
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
An investigation on behalf of current long term investors in Novo Nordisk A/S (NYSE: NVO) shares.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in NYSE: NVO stocks follows a lawsuit filed against Novo Nordisk A/S over alleged securities laws violations. The investigation on behalf of long term investors in NYSE: NVO stocks, concerns whether certain officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that, the Defendants made materially false and misleading statements concerning Novo's REDEFINE-1 Study. The Complaint further alleges that on December 20, 2024, Defendants disclosed information that was directly related to their prior misrepresentations and material omissions concerning Novo's REDEFINE-1 Study and that this disclosure had the effect of correcting Defendants' prior false and/or misleading statements which, in turn, caused Novo's stock price to decline as investors reassessed the risks and benefits of investing in the Company.
Those who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing here
News-ID: 4200387 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit Alert: Investors who lost money with shares of RCI Hospitality Holdings, …
An investor, who purchased shares of RCI Hospitality Holdings, Inc. (NASDAQ: RICK), filed a lawsuit over alleged violations of Federal Securities Laws by RCI Hospitality Holdings, Inc.
Investors who purchased shares of RCI Hospitality Holdings, Inc. (NASDAQ: RICK) have certain options and for certain investors are short and strict deadlines running. Deadline: November 20, 2025. NASDAQ: RICK investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Novo
Novo Nordisk's "Employee Diet" Trims Workforce By 9,000
Novo Nordisk (NYSE: NVO) just put 9,000 employees on the chopping block [https://finance.yahoo.com/news/novo-just-fired-9-000-172419344.html] in what it's calling an effort to "reduce complexity." Translation: the world's onetime obesity drug darling is cleaning house after years of chasing growth that turned into bloat.
A year ago, Novo was Europe's most valuable company, sitting atop the GLP-1 boom like a king fattened on its own miracle cure. Today, it's a retrenchment story. The stock…
Diabetes Therapeutic Market Innovations, Competitive Analysis, New Business Deve …
The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries…
Growth Hormone Deficiency Therapeutics- Pipeline Analysis 2018 | Novo Nordisk
Growth hormone deficiency is a congenital or acquired hormonal disorder, that is characterized by short stature due to lack of growth hormone. The disease can cause change in muscle mass, bone strengths, and cholesterol levels.
Download the sample report @ https://www.pharmaproff.com/request-sample/1076
This condition is found to be related to the mutation in POU1F1/Pit1, PROP1 GHRH and GH1 genes. Puberty is generally delayed or absent in adolescents with growth hormone deficiency.
Get the…
Hormonal Replacement Therapeutics - Pipeline Analysis 2018 | Novo Nordisk
Hormonal replacement therapy is a type of treatment wherein patients receive a course of hormones in order to get relieve from the menopause related problems. The therapy involves administration of synthetic estrogen and progesterone to overcome decreasing hormone level of women.
Download the sample report @ https://www.pharmaproff.com/request-sample/1136
The most common signs and symptoms observed in patients with decreased hormone level are irregular menstrual cycles, and psychological symptoms (mood swings, anxiety, and…
Antidiabetics Market Size, Historical Growth Analysis By top Key Player - Boehri …
Market Study Report: The Report entitled 2018-2024 Global Antidiabetics Market Report explores the essential factors of the Antidiabetics market considering such as industry situations, market demands, market players adopted business strategies and their growth scenario. The Global Antidiabetics market has been separated by this report based on the key players profiles, Type, Application and Regions.
Germany antidiabetics industry accounted for largest revenue size of USD 4,461.7 million of Europe antidiabetics industry…
Global Recombinant DNA Technology Market 2025 : Monsanto Company, Pfizer Inc., N …
Researchmoz added Most up-to-date research on "Global Recombinant DNA Technology Market Size,Status and Forecast 2025" to its huge collection of research reports.
This report studies the global Recombinant DNA Technology market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Recombinant DNA Technology market by companies, region, type and end-use industry.
In 2017, the global Recombinant DNA Technology market size was million US$ and it…
